Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncothyreon has completed the transfer of certain assays and manufacturing technology related to Stimuvax to Merck KGaA, triggering a payment to Oncothyreon of $3 million.
Subscribe to our email newsletter
The payment will be made under the terms of the amended and restated supply agreement signed in August 2007.
Stimuvax (BLP25 liposome vaccine) is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. Merck KGaA currently is conducting a global Phase III trial to evaluate patients with documented unresectable non-small cell lung cancer.